Therapeutics News and Research

RSS

Wireless near-infrared spectroscopy can effectively detect bladder disease in children

A cell phone-sized, wireless near-infrared device is as reliable as the current "gold standard" invasive tests in determining bladder disease, according to a study by researchers at the University of British Columbia, Vancouver Coastal Health and the Child & Family Research Institute (CFRI).

1 Jun 2011

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

AVEO Pharmaceuticals, Inc. today announced it has entered into an exclusive license agreement with Centocor Ortho Biotech Inc. for the worldwide development and commercialization of AVEO's internally-discovered antibodies targeting the RON receptor.

1 Jun 2011

FDA approves Oceana's Solesta for treatment of fecal incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.

31 May 2011

Almac's main research projects on ovarian, breast cancer to be presented at ASCO 2011

Two of Almac's main research projects have been selected for presentation at the 2011 ASCO meeting. Both of these studies are based on Almac's approach of profiling large clinical datasets and analysing the data for molecular subgroups that can aid in improved diagnosis of cancer by identifying molecular subtypes and by identifying molecular subgroups which are of clinical and therapeutic relevance.

31 May 2011

Heptares, AstraZeneca partner to discover and develop new GPCR drug targets

AstraZeneca and Heptares Therapeutics today announced they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors.

31 May 2011

Scientists study key malaria protein structure to demonstrate how cells grow and move

Researchers from the Walter and Eliza Hall Institute have overturned conventional wisdom on how cell movement across all species is controlled, solving the structure of a protein that cuts power to the cell 'motor'. The protein could be a potential drug target for future malaria and anti-cancer treatments.

31 May 2011

Oceana Therapeutics receives FDA approval for Solesta injectable gel to treat fecal incontinence

The U.S. Food and Drug Administration today approved a sterile, injectable gel to treat fecal incontinence in patients for whom other therapies such as diet change, fiber therapy or anti-motility medications failed.

30 May 2011

Tacrolimus prevents breast cancer growth in pre-clinical studies

Tacrolimus, a drug that is commonly used to prevent organ transplantation rejection, inhibits breast cancer growth in pre-clinical studies. The finding from UNC scientists was reported in the May 26th PLoS ONE.

27 May 2011

New genomics research on abnormal brain development

Local researchers are finally on the road to developing targeted treatments for serious, life-long disabilities such as autism and schizophrenia, thanks to new genomics research focusing on abnormal brain development.

27 May 2011

Naturally occurring plant alkaloids could help prevent, delay memory loss linked with Alzheimer's

A family of naturally occurring plant compounds could help prevent or delay memory loss associated with Alzheimer's disease, according to a new study by the Translational Genomics Research Institute.

27 May 2011

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Pro-Pharmaceuticals, Inc. today announced that it has changed its name to Galectin Therapeutics Inc. to more accurately reflect the Company's core expertise in galectin science and its leading platform for the creation of galectin inhibitors to treat serious diseases including fibrosis and cancer.

27 May 2011

Investigators receive NIH grant to help move gene therapy for MPS IIIB toward clinical trials

Investigators at Nationwide Children's have received a grant from the National Institutes of Health to help move a therapy for MPS IIIB that has been shown effective in mice toward clinical trials in humans.

26 May 2011

Comprehensive insight into current neural stem cell research and therapies

A new article published by Cell Press in the May 26 issue of the journal Neuron provides comprehensive insight into the current status of neural stem cell research and the sometimes labyrinthine pathways leading to stem cell-based therapies.

26 May 2011

Paxil and Pravachol in combination cause unexpected increase in blood glucose levels

A widely used combination of two common medications may cause unexpected increases in blood glucose levels, according to a study conducted at the Stanford University School of Medicine, Vanderbilt University and Harvard Medical School. Researchers were surprised at the finding because neither of the two drugs - one, an antidepressant marketed as Paxil, and the other, a cholesterol-lowering medication called Pravachol - has a similar effect alone.

26 May 2011

Comtex SmarTrend ranks POZEN as second most efficient pharmaceutical company

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that Comtex SmarTrend has ranked POZEN as the second most efficient company in the pharmaceutical industry.

25 May 2011

Pathway receives FDA approval to commence PWT33597 Phase 1 study in advanced solid tumors

Pathway Therapeutics, Inc., a company developing novel therapeutics that target the PI3K and mTOR pathways, today announced that the FDA has accepted an IND filing for PWT33597, which allows Pathway to commence Phase 1 clinical testing.

25 May 2011

PPSC, InVivo enter sponsorship deal to support Adaptive Sailing Program for the disabled

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today announced that the Company has entered into a sponsorship agreement with Boston-based Piers Park Sailing Center to support a non-profit sailing initiative for the disabled.

25 May 2011

CRT, Cancer Research UK and Centella partner to launch clinical development of CEN-209

Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.

25 May 2011

Elan, Proteostasis create innovative drug discovery initiative for neurodegenerative disorders

Proteostasis Therapeutics and Elan Corporation today announced a strategic business relationship to advance Proteostasis' platform for the discovery and development of disease-modifying, small molecule drugs and diagnostics for the treatment of neurodegenerative disorders such as Parkinson's, Huntington's, multiple sclerosis and amyotrophic lateral sclerosis, and a broad array of dementia-related diseases including Alzheimer's.

25 May 2011

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

PsychoGenics Inc. today announced that it has entered into a strategic alliance with Evotec AG to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies.

25 May 2011

Therapeutics News and Research

Wireless near-infrared spectroscopy can effectively detect bladder disease in children

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

FDA approves Oceana's Solesta for treatment of fecal incontinence

Almac's main research projects on ovarian, breast cancer to be presented at ASCO 2011

Heptares, AstraZeneca partner to discover and develop new GPCR drug targets

Scientists study key malaria protein structure to demonstrate how cells grow and move

Oceana Therapeutics receives FDA approval for Solesta injectable gel to treat fecal incontinence

Tacrolimus prevents breast cancer growth in pre-clinical studies

New genomics research on abnormal brain development

Naturally occurring plant alkaloids could help prevent, delay memory loss linked with Alzheimer's

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Investigators receive NIH grant to help move gene therapy for MPS IIIB toward clinical trials

Comprehensive insight into current neural stem cell research and therapies

Paxil and Pravachol in combination cause unexpected increase in blood glucose levels

Comtex SmarTrend ranks POZEN as second most efficient pharmaceutical company

Pathway receives FDA approval to commence PWT33597 Phase 1 study in advanced solid tumors

PPSC, InVivo enter sponsorship deal to support Adaptive Sailing Program for the disabled

CRT, Cancer Research UK and Centella partner to launch clinical development of CEN-209

Elan, Proteostasis create innovative drug discovery initiative for neurodegenerative disorders

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News